RT Journal Article SR Electronic T1 Interregional SARS-CoV-2 spread from a single introduction outbreak in a meat-packing plant in northeast Iowa JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.08.20125534 DO 10.1101/2020.06.08.20125534 A1 Richmond, Craig S. A1 Sabin, Arick P. A1 Jobe, Dean A. A1 Lovrich, Steven D. A1 Kenny, Paraic A. YR 2020 UL http://medrxiv.org/content/early/2020/06/12/2020.06.08.20125534.abstract AB SARS-CoV-2 spread has proven to be especially difficult to mitigate in high risk settings, including nursing homes, cruises, prisons and various industrial settings. Among industrial settings, meat processing facilities in the United States have experienced particularly challenging outbreaks. We have sequenced SARS-CoV-2 whole viral genomes from individuals testing positive in an integrated regional healthcare system serving 21 counties in southwestern Wisconsin, northeastern Iowa and southeastern Minnesota, providing an overview of SARS-CoV-2 introduction and spread in a region spanning multiple jurisdictions with differing mitigation policies. While most viral introductions we detected were contained with only minor transmission chains, a striking exception was an outbreak associated with a meatpacking plant in Postville, IA. In this case, a single viral introduction led to unrestrained spread within the facility, affecting many staff and members of their households. Importantly, by surveilling viral sequences from the surrounding counties, we have documented the spread of this SARS-CoV-2 substrain from this epicenter to individuals in 13 cities in 7 counties in Iowa, Wisconsin and Minnesota, a region spanning 185 square miles. This study highlights the regional public health consequences of failures to rapidly act to mitigate viral spread in a single industrial setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Gundersen Medical Foundation. No external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Gundersen Health System Institutional Review Board (#2-20-03-008; PI: Kenny)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesConsensus sequence data on all viral substrains has been submitted to GISAID. https://www.gisaid.org/